CAPR - Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

• On May 13, 2020, "Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002".
• On Sept 24, 2021, "Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002".
• The two "final" results are reporting the same 12-month data from the same 20 enrolled DMD patients in the same phase 2 trial.
• The first "final" results in May 2020 missed the pre-specified primary end point, but the second "final" results in Sept 2021 met all the end points with statistical significance.
• I take a close look and share my thoughts here.

For further details see: